Zum Inhalt

Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach

  • 05.01.2024
  • short review
Erschienen in:

Summary

The biomarker developments in adenocarcinomas of the esophagus, gastroesophageal junction, and stomach are currently very exciting. Clinical trial data for Claudin 18.2 and FGFR2b are promising and EMA approvals are expected. Routine testing includes PD-L1, HER2, and MSI.
Titel
Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
Verfasst von
Dr. Katja Schmitz
Publikationsdatum
05.01.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00950-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.